Journal article
The Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists on Cardiorenal Outcomes: Systematic Review and Meta-analysis
Abstract
BACKGROUND: Evidence for the cardiorenal risk reduction properties of antihyperglycemic medications originally prescribed for type 2 diabetes, sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) is rapidly emerging. We completed a meta-analysis of recent literature to provide evidence-based estimates of benefit across various populations and outcomes.
METHODS: We searched Medline and …
Authors
Ali MU; Mancini GBJ; Fitzpatrick-Lewis D; Lewis R; Jovkovic M; Zieroth S; O'Meara E; Connelly KA; Sherifali D
Journal
Canadian Journal of Cardiology, Vol. 38, No. 8, pp. 1201–1210
Publisher
Elsevier
Publication Date
August 2022
DOI
10.1016/j.cjca.2022.05.011
ISSN
0828-282X